VirtualData-Room.com
Compare providers
DealRoom · June 16, 2026

How a small corp dev team uses AI, from blind teasers to document review

Alex Abbott and Matthew Golden run M&A in-house at Sellers Dorsey, a PE-backed healthcare firm with no dedicated M&A counsel. They explain where AI already saves them hundreds of hours, where it stops, and how patient data and legal privilege limit what they let it touch.

  • Alex Abbott · Associate Director of Corporate Strategy and Development, Sellers Dorsey
  • Matthew Golden · Associate General Counsel, Sellers Dorsey
Explore further
Watch on YouTube DealRoom
DealRoom · 13 min Watch on YouTube ↗
Key points
  • Sellers Dorsey uses AI most in early deal work: market research, sourcing and preliminary diligence that used to take hours now take minutes.
  • Matthew Golden says AI document review saved hundreds of hours of legal work on the firm's last acquisition, with no discernible errors.
  • Golden puts AI at associate counsel level for issue spotting, not yet at higher level analysis, and the team uses no agents for legal work.
  • Alex Abbott wants to feed context on both companies, plus the team's own deal postmortems, into AI to plan integration and catch decision biases.
  • Protected health information and legal privilege set hard limits: no free tools or personal licences for confidential material, only enterprise tools with known terms.
  • Both say the decision on whether to buy a business should stay with human leadership.

When a blind teaser lands at Sellers Dorsey, the corporate development team pastes it into a large language model and asks which company it thinks this is, based on the context in the teaser. Alex Abbott, the firm's associate director of corporate strategy and development, calls it something fun they have been playing with (around 1:13). It shows where AI sits for this team today: in the early grunt work of a deal, the market research, sourcing and preliminary diligence that used to take hours and now takes minutes.

“Something fun that we've been playing with, too, is whenever we receive a blind teaser, we will plug that into an LLM and say, 'Hey, which company do you think this is based on the context information in the teaser?'”

Alex Abbott, Associate Director of Corporate Strategy and Development, Sellers Dorsey

Sellers Dorsey is a PE-backed healthcare firm of about 300 people that has made acquisitions to build its product and technology side. Its in-house M&A team is small, Abbott says, and runs the whole process from deal strategy and sourcing to diligence and long-term integration. Matthew Golden, associate general counsel, heads up the due diligence. There is no dedicated M&A counsel, he says, so the deal work happens on top of the normal work. The session is part of DealRoom's AI for M&A Summer School, and both speakers use DealRoom.

“Issue spotting is where it's great at right now. Associate counsel level work in terms of issue spotting, but that next level analysis, we haven't moved far up the food chain on it.”

Matthew Golden, Associate General Counsel, Sellers Dorsey

Golden's clearest result is in document review. On the first acquisition a few years ago there was no AI-enabled tool, and all the review was very manual, very tedious. On later deals AI cut the majority of that time. He calls document review the lowest hanging fruit in legal work. Gone are the days, in his words, when you had to train it to recognise a certain clause or the phrasing had to be exact. On the last acquisition it saved hundreds of hours with no discernible errors (around 10:39).

“On the legal side, the document review was the fastest adoption. That saved hundreds of hours of legal work on our last acquisition. No discernible errors or anything like that.”

Matthew Golden, Associate General Counsel, Sellers Dorsey

He is just as clear about the ceiling. AI is great at issue spotting, at roughly associate counsel level, Golden says, but has not moved far up the food chain into the next level of analysis, and the team is not using agents for any legal work. Abbott uses it on the corporate development side to pressure test the investment thesis, asking what they haven't thought of yet and what gaps it sees in their rationale. Human judgement, Abbott says, should come before anything you put into AI.

“We could get to a point where AI could answer almost everything analytical except for the question should we do this deal or not.”

Alex Abbott, Associate Director of Corporate Strategy and Development, Sellers Dorsey

Both draw a hard line at the decision itself. Abbott says this is a people job first and foremost. Selling your business is a scary thing, and getting a founder through saying yes, then diligence, then being absorbed by a much larger company takes relationship building and trust that Abbott doesn't see AI ever replacing. The call on whether to buy should remain in the hands of human leadership. Abbott hopes AI could one day answer almost everything analytical except that question (around 6:28).

The bigger upside, in Abbott's view, is integration. AI thrives on context, Abbott says, so the team could build a persona from everything it can provide about its own organisation, gather as much context as possible on a target, feed both in and ask how it would reimagine the org chart or roll out an integration timeline. The team has also written up lessons learned and postmortems from past deals. Abbott wants to feed those in too, so the model acts as a checker that catches decision biases and doesn't let anything slip past the goalie.

The risks are specific to this firm. Recent acquisitions brought it into protected health information, in one of the most regulated industries, so any tool has to be deployed very deliberately, safely and securely, Abbott says, and staff need to know not to put PHI into AI tools. The firm is rolling out Claude across its roughly 300 employees, and Golden says Anthropic provided a high trust compliant version for enterprise use. He also flags privilege issues with LLMs if you don't have an enterprise licence or an agreement you are comfortable with (around 3:45).

Adoption at the firm is voluntary and, in Abbott's words, very person differentiated, with early adopters on one side and the more reticent on the other. Golden sees the same split across the legal profession, enthusiasm on one hand and hesitation over privacy, confidentiality and privilege on the other. He calls it a K-shaped adoption. The advice from both starts with paperwork. Read your organisation's AI policy, Abbott says, and if there isn't one, get one today. Golden adds: read the terms of service, never use free AI tools or a personal licence for anything confidential, and ask where the boundaries are.

Why it matters

Golden's warning about privilege and personal licences applies to anyone reviewing data room documents with AI. Before a deal team runs a target's contracts through a model, check which tool it is, under which licence, and what its terms say about the data.

Summary and analysis by VirtualData-Room.com from the public video. Play it above; the original source is linked there.